Topic resource collection
Approved comparison material connected to this topic.
774 resourcesRead both sides
Thymalin Restores thymopoiesis; normalises T-cell maturation and reduces inflammatory cytokines 38% reduction in fatigue scores in post-viral syndrome patients (10-day course, Russian clinical data) 5–10mg subcutaneous, 5–10 cons…
Cerebrolysin BDNF/NGF mimetic, PI3K/Akt activation Moderate (requires prolonged administration) 10–30 mL/kg IV in animal models 2–8°C, sterile solution, light-protected Gold standard for ischemic injury models but requires strict…
GHK-Cu (copper peptide) Integrin receptor binding → MMP-2 upregulation + TIMP activation Randomized controlled trials in humans (Level 1) Inflammatory through proliferative 1–2% topical cream or serum Strongest evidence base for …
CJC-1295 + Ipamorelin GHRH + ghrelin receptor agonism → pulsatile GH 6–9% body fat reduction 45–60% above baseline High. Minimal effect without resistance training Gold standard for GH-mediated body recomposition; requires struct…
Before integrating peptides into any joint health protocol, understanding how they compare to established interventions. And to each other. Is critical. NSAIDs (ibuprofen, naproxen) COX enzyme inhibition → reduced prostaglandin s…
BPC-157 FAK-paxillin pathway activation, VEGF/bFGF upregulation, MMP-9 inhibition Preclinical models show 38–43% improvement in tendon healing and cartilage preservation; no Phase 3 human trials 200–500 mcg daily subcutaneous inj…
Before considering any peptide intervention, understand the evidence strength, administration route, documented mechanisms, and realistic outcome expectations across the most-studied compounds. Semax BDNF/NGF upregulation via mel…
The table below contrasts peptides for ADHD with FDA-approved stimulant medications across mechanism, evidence base, regulatory status, and clinical utility. Prescription Stimulants (methylphenidate, amphetamine) Dopamine and nor…
BPC-157 VEGF upregulation, angiogenesis, fibroblast recruitment 250–500 mcg/day Subcutaneous or IM near injury site Preclinical animal studies; no Phase 3 human trials Most robust preclinical data for acute soft tissue injury; la…
KPV (lysine-proline-valine) Inhibits NF-κB inflammatory signaling; melanocortin receptor agonist Oral (enteric-coated) or subcutaneous 500 mcg 3x daily (oral); 200–300 mcg daily (subQ) Pilot human trial in IBD; animal models in c…
Selank GABAergic modulation, monoamine metabolism 4 RCTs (n=312 total) 0.15% solution, 3 drops per nostril 2× daily Intranasal Modest evidence for short-term anxiety reduction. Effect size is clinically detectable but not transfo…
BPC-157 (local injection) VEGF upregulation, angiogenesis promotion 4–8 weeks for pain reduction, 12+ weeks for structural improvement Case series, animal models. No Phase 3 RCTs Most direct mechanism for hypoxic tendon tissue; r…
Growth Hormone Secretagogues (e.g., MK 677) Ghrelin receptor agonism → pulsatile GH/IGF-1 elevation Lipolysis via hormone-sensitive lipase; shifts substrate preference to fat oxidation Investigating metabolic effects of restored …
BPC-157 Upregulates VEGF and FGF-2 for mucosal healing; restores tight junction protein synthesis 250–500 mcg/day Subcutaneous or oral Animal models (robust); human data (limited) Strongest mechanistic evidence for structural bar…
This table compares the primary peptide classes used in body recomposition research based on mechanism, evidence quality, and practical application. Growth Hormone Secretagogues (GHRP-2, CJC-1295) Stimulate pulsatile GH release v…
GH Secretagogues (CJC-1295/Ipamorelin) Stimulates endogenous GH release, increases lipolysis via hormone-sensitive lipase activation 6–9% reduction in visceral adipose tissue over 12 weeks (JCEM study) Subcutaneous injection, 5 d…
BPC-157 VEGF upregulation, angiogenesis stimulation, collagen synthesis activation via growth hormone receptor binding Tendons, ligaments, joint capsules, cartilage 200–500 mcg daily (animal studies); human dosing extrapolated fr…
BPC-157 200–500 mcg daily Subcutaneous injection or oral (enteric-coated) VEGF upregulation, tight junction protein expression, NOS pathway activation 7–14 days for barrier markers; 21+ days for mucosal healing Strongest evidence…
BPC-157 Tendons, ligaments, GI mucosa Upregulates VEGF receptors, stabilizes nitric oxide Days 5–21 post-injury Strongest evidence in connective tissue repair; localized injection outperforms systemic TB-500 Muscle, ligaments, so…
BPC-157 VEGF upregulation, tight junction stabilization, enteric nervous system modulation 47+ animal studies; no human trials Subcutaneous or oral (enteric-coated) Requires -20°C storage; degrades in gastric acid without protect…